Showing results (451-460 of 561) with videos related to
Sort By:
Pageof 57
The Lancet. Oncology|December 17, 2013
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trialHugo E R Ford, Andrea Marshall, John A Bridgewater, et al.Structure (London, England : 1993)|September 10, 2003
X-ray crystallographic and kinetic studies of human sorbitol dehydrogenaseThomas A Pauly, Jennifer L Ekstrom, David A Beebe, et al.Acta Oncologica (Stockholm, Sweden)|February 15, 2021
Adjuvant therapy following neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma in patients with clear resection marginsRebecca K Bott, Kerri Beckmann, Janine Zylstra, et al.British Journal of Haematology|May 22, 2020
Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trialMary Gleeson, Nicholas Counsell, David Cunningham, et al.Trials|August 31, 2017
A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trialNick J Battersby, Mit Dattani, Sheela Rao, et al.British Journal of Haematology|August 2, 2016
Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trialMary Gleeson, Eliza A Hawkes, David Cunningham, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 6, 2018
Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL)Qian Shi, Norbert Schmitz, Fang-Shu Ou, et al.The Journal of Molecular Diagnostics : JMD|March 10, 2015
Technical reproducibility of single-nucleotide and size-based DNA biomarker assessment using DNA extracted from formalin-fixed, paraffin-embedded tissuesShenli Zhang, Iain B Tan, Nur S Sapari, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2009
Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancerDavid Cunningham, Ian Chau, Deborah D Stocken, et al.The Lancet. Oncology|September 22, 2014
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trialHansjochen Wilke, Kei Muro, Eric Van Cutsem, et al.Pageof 57